Affinage

YTHDF1

YTH domain-containing family protein 1 · UniProt Q9BYJ9

Length
559 aa
Mass
60.9 kDa
Annotated
2026-04-28
100 papers in source corpus 43 papers cited in narrative 43 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

YTHDF1 is an N6-methyladenosine (m6A) reader protein that functions as a master translational regulator, recognizing m6A-modified mRNAs through its YTH domain and promoting their ribosome-associated translation across diverse biological contexts including neuronal plasticity, intestinal stem cell maintenance, innate and adaptive immunity, and tumorigenesis (PMID:30401835, PMID:30728504, PMID:32064749, PMID:33999206). YTHDF1 recruits translation machinery — interacting with partners such as RUVBL1/2 at 40S initiation complexes, eIF5B, and DDX60 — to selectively enhance protein output from target transcripts encoding cell cycle regulators (CDK2, CDK4, cyclin E2), signaling effectors (EZH2, YAP, p65/RelA), and lysosomal proteases (cathepsins), without necessarily altering mRNA abundance (PMID:38900944, PMID:39672819, PMID:33999206, PMID:31653849, PMID:37459919). Beyond translation, YTHDF1 participates in mRNA degradation through AGO2 interaction and P-body phase separation, sequesters m6A-modified mRNAs in stress granules to protect them under cellular stress, and its activity is regulated by post-translational modifications including O-GlcNAcylation (controlling nuclear export via CRM1) and lactylation (triggering its own degradation) (PMID:34821414, PMID:37857002, PMID:37086786, PMID:39496835). YTHDF1 translational activity is gated by FMRP, which sequesters YTHDF1 from ribosomes until neuronal stimulation-induced FMRP phosphorylation releases it, coupling epitranscriptomic translation control to synaptic activity (PMID:37949069).

Mechanistic history

Synthesis pass · year-by-year structured walk · 13 steps
  1. 2018 High

    Establishing YTHDF1 as a stimulus-dependent translational enhancer resolved how m6A marks are decoded into protein output in neurons, linking epitranscriptomic reading to synaptic plasticity and memory.

    Evidence Ythdf1 KO mice, hippocampal knockdown, nascent protein labeling, tether reporter assays, and electrophysiology in adult mouse hippocampus

    PMID:30401835

    Open questions at the time
    • Mechanism of YTHDF1 recruitment to ribosomes not defined
    • Whether translational enhancement requires co-factors was unknown
    • Specificity determinants beyond m6A recognition not identified
  2. 2019 High

    Identifying specific translational targets — lysosomal cathepsins in dendritic cells and Robo3.1 in commissural neurons — demonstrated that YTHDF1 selectively controls functionally coherent mRNA programs in distinct cell types, with immunological consequences for tumor antigen cross-presentation.

    Evidence Ythdf1 KO mice with tumor immunology readouts, cathepsin inhibition rescue; m6A site mutagenesis and YTHDF1 RIP in spinal neurons with axon guidance phenotyping

    PMID:30728504 PMID:30843071

    Open questions at the time
    • How YTHDF1 target selectivity arises among thousands of m6A-marked transcripts remained unclear
    • Whether YTHDF1 interacts directly with the translation initiation machinery was unknown
  3. 2019 Medium

    Extending YTHDF1 translational targets to cell cycle regulators (CDK2, CDK4, cyclin D1) in NSCLC broadened its role from specialized neuronal/immune contexts to a general pro-proliferative factor in cancer.

    Evidence YTHDF1 depletion with translational efficiency measurements and xenograft tumor models in NSCLC cells

    PMID:31653849

    Open questions at the time
    • Translational mechanism (initiation vs. elongation) not dissected
    • Contribution of YTHDF1 vs. other YTH readers to cell cycle mRNA translation not resolved
  4. 2020 High

    Discovery that YTHDF1 amplifies overall translational capacity by promoting translation of the translation initiation factor EIF3C, and that it drives Wnt-dependent intestinal stemness via TCF7L2 translation, revealed feedforward circuits coupling m6A reading to global and pathway-specific protein synthesis.

    Evidence Multi-omics (m6A-seq, proteomics, RIP) and luciferase assays in ovarian cancer; Ythdf1 KO mice in intestinal regeneration and Wnt activation models

    PMID:31996915 PMID:32064749

    Open questions at the time
    • Whether EIF3C-mediated amplification operates in non-cancer contexts was untested
    • Structural basis for YTHDF1-ribosome interaction unknown
  5. 2021 High

    Identification of the P/Q/N-rich domain interaction with DDX60 DEAD domain for TRAF6 translation, and demonstration that YTHDF1 promotes AGO2-dependent mRNA degradation through P-body phase separation, established that YTHDF1 has dual roles in both translation and mRNA decay mediated by distinct protein partners.

    Evidence Domain-level Co-IP, Ribo-seq, m6A-seq, and bacterial infection model for TRAF6; CRISPR KO, 4SU-TT-seq, in vitro phase separation reconstitution, and FRAP for AGO2/P-body function

    PMID:33999206 PMID:34821414

    Open questions at the time
    • Whether translation promotion and mRNA decay functions operate on overlapping or distinct mRNA populations was unclear
    • What determines whether YTHDF1 channels a target to translation vs. decay was unresolved
  6. 2021 High

    Broadening of verified YTHDF1 translational targets to autophagy regulators (ATG2A/ATG14), YAP, and bone-regulatory ZNF839 across hepatocellular carcinoma, cardiomyocytes, and BMSCs, combined with identification of HIF-1α as a direct transcriptional inducer of YTHDF1, positioned YTHDF1 as a hypoxia-responsive translational amplifier.

    Evidence Polysome profiling, MeRIP-seq, ChIP on YTHDF1 promoter in HCC; KO mice with bone mass phenotype; iPSC-derived cardiomyocyte epistasis experiments

    PMID:33456585 PMID:33619246 PMID:34772913

    Open questions at the time
    • Whether HIF-1α-YTHDF1 axis operates outside cancer/hypoxia contexts was untested
    • Relationship between YTHDF1's translational and stability-regulating activities on same targets not clarified
  7. 2022 High

    O-GlcNAcylation of YTHDF1 at Ser196/197/198 was shown to promote cytosolic localization via enhanced CRM1 binding, establishing the first post-translational mechanism governing YTHDF1 subcellular distribution and functional output.

    Evidence OGT Co-IP, site-directed mutagenesis, CRM1 binding assays, molecular dynamics simulation, and xenograft validation in colorectal cancer

    PMID:37086786

    Open questions at the time
    • Other PTMs controlling YTHDF1 localization or activity not yet mapped systematically
    • Whether O-GlcNAcylation affects target mRNA selectivity was unknown
  8. 2022 High

    YTHDF1 was linked to cerebellar axon growth regulation through Dvl1 translation and shown to regulate NLRP3 inflammasome activation through both direct NLRP3 translation and indirect WWP1-mediated ubiquitination, expanding its roles in neurodevelopment and innate immunity.

    Evidence RIP-seq, quantitative proteomics, conditional KO in cerebellar granule cells; RIP, dual-luciferase, meRIP, and in vivo CLP sepsis models for NLRP3/WWP1

    PMID:34643063 PMID:35508474 PMID:35649302

    Open questions at the time
    • Whether YTHDF1 and YTHDF2 competition or cooperation on overlapping targets is context-dependent remained unclear
    • Stoichiometry of YTHDF1 in inflammasome regulation not defined
  9. 2023 High

    Discovery that FMRP sequesters YTHDF1 from ribosomes and releases it upon phosphorylation during neuronal stimulation established a gating mechanism for activity-dependent translation, directly linking YTHDF1 to Fragile X syndrome pathophysiology.

    Evidence Co-IP of FMRP-YTHDF1, ribosome association assays, phosphorylation studies, FXS organoid model with small-molecule YTHDF1 inhibitor

    PMID:37949069

    Open questions at the time
    • Identity of kinase phosphorylating FMRP to release YTHDF1 not defined in this context
    • Whether FMRP-YTHDF1 gating occurs outside neurons was untested
  10. 2023 High

    Multiple studies converged on YTHDF1 as a driver of tumor immune evasion — through p65/CXCL1-mediated MDSC recruitment, EZH2/IL-6-driven MDSC activation, and lysosomal proteolysis of MHC-I — establishing YTHDF1 as a therapeutic target for cancer immunotherapy.

    Evidence Ythdf1 KO/knockin mice with integrated Ribo-seq, MeRIP-seq, scRNA-seq across colorectal cancer, NASH-HCC, and multiple tumor models; MHC-I surface expression assays

    PMID:36650153 PMID:36717220 PMID:37459919

    Open questions at the time
    • Whether YTHDF1 inhibition synergizes with checkpoint immunotherapy in patients was untested
    • Relative contribution of DC-intrinsic vs. tumor-intrinsic YTHDF1 to immune evasion not quantified
  11. 2023 High

    Identification of RUVBL1/2 as YTHDF1 interactors at 40S initiation complexes, discovered through CRISPR screening and confirmed by Co-IP/mass spectrometry, provided the first direct mechanistic link between YTHDF1 and the translation initiation machinery.

    Evidence CRISPR screen, Co-IP/mass spectrometry, Ribo-seq, pharmacological inhibition with CB6644 in vivo

    PMID:38900944

    Open questions at the time
    • Whether RUVBL1/2 are required for all YTHDF1-driven translation or only a subset of targets was unknown
    • Structural basis of YTHDF1-RUVBL1/2-40S interaction not resolved
  12. 2024 Medium

    YTHDF1 was shown to accumulate m6A-modified mRNAs in stress granules to protect pro-survival transcripts from degradation during acute kidney injury, and lactylation was identified as a PTM that triggers YTHDF1 degradation during viral infection, revealing context-dependent regulation of YTHDF1 stability and RNA triage function.

    Evidence Tubular-specific YTHDF1 KO mice with AKI models and SG co-localization; lactylation mass spectrometry and SFTSV infection models

    PMID:37857002 PMID:39496835

    Open questions at the time
    • Whether stress granule sequestration and translational promotion are temporally separated activities of YTHDF1 was unclear
    • Lactylation site on YTHDF1 not mapped to specific residues in these studies
    • Independent confirmation of SG-protective function in non-renal tissues needed
  13. 2024 Medium

    YTHDF1 was found to interact with eIF5B to promote PD-L1 translation and to degrade RIG-I mRNA under methionine-rich conditions, revealing a metabolic input that coordinates YTHDF1's dual translation/decay activities to promote immune evasion.

    Evidence IP/mass spectrometry for YTHDF1-eIF5B interaction, PD-L1 translation assays, scRNA-seq, MB49 mouse tumor models

    PMID:39672819

    Open questions at the time
    • Whether eIF5B interaction is methionine-dependent or constitutive was not fully resolved
    • Mechanism by which methionine elevates YTHDF1 activity not defined

Open questions

Synthesis pass · forward-looking unresolved questions
  • Key unresolved questions include the structural basis for YTHDF1's selective engagement with translation initiation complexes versus decay machinery, the rules governing target mRNA selection among thousands of m6A-marked transcripts, and whether therapeutic YTHDF1 inhibition can safely enhance antitumor immunity without disrupting critical homeostatic functions in neurons and stem cells.
  • No high-resolution structure of YTHDF1 in complex with ribosomal initiation factors
  • Determinants of translation vs. decay fate decision for individual m6A-mRNAs unknown
  • No clinical data on YTHDF1 inhibitor safety or efficacy

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0045182 translation regulator activity 13 GO:0003723 RNA binding 8 GO:0098772 molecular function regulator activity 3
Localization
GO:0005829 cytosol 4 GO:0005634 nucleus 1
Pathway
R-HSA-392499 Metabolism of proteins 13 R-HSA-168256 Immune System 8 R-HSA-162582 Signal Transduction 4 R-HSA-1266738 Developmental Biology 3 R-HSA-8953854 Metabolism of RNA 3 R-HSA-1640170 Cell Cycle 2 R-HSA-9612973 Autophagy 2
Partners
AGO2CRM1DDX60EIF5BFMRPRBMS1RUVBL1RUVBL2

Evidence

Reading pass · 43 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2018 YTHDF1 promotes translation of m6A-methylated neuronal mRNAs in response to neuronal stimulation in the adult mouse hippocampus, facilitating learning and memory. Nascent protein labeling and tether reporter assays showed YTHDF1 enhances protein synthesis in a stimulus-dependent manner; hippocampus-specific knockout or knockdown of Ythdf1 impaired synaptic transmission and long-term potentiation. Ythdf1 knockout mice, hippocampus-specific knockdown (AAV), transcriptome-wide YTHDF1 binding/m6A mapping, nascent protein labeling, tether reporter assay, synaptic electrophysiology Nature High 30401835
2019 In dendritic cells, YTHDF1 binds m6A-marked transcripts encoding lysosomal proteases (cathepsins) and increases their translation, thereby enhancing lysosomal degradation of antigens and suppressing cross-presentation of tumor antigens to CD8+ T cells. Loss of YTHDF1 in classical dendritic cells elevated neoantigen-specific CD8+ T cell responses and antitumor immunity. Ythdf1 knockout mice, in vivo cross-presentation assays, cathepsin inhibition rescue experiments, tumor immunology readouts Nature High 30728504
2019 YTHDF1 binds m6A-modified Robo3.1 mRNA in spinal commissural neurons and promotes its translation without affecting mRNA levels. Mutation of m6A sites in Robo3.1 mRNA, YTHDF1 knockdown, or neuron-specific Ythdf1 knockout each reduced Robo3.1 protein and caused pre-crossing axon guidance defects. YTHDF1 RIP, m6A site mutagenesis, YTHDF1 KO/KD in spinal neurons, protein vs. mRNA quantification, in vivo axon guidance analysis Nucleic acids research High 30843071
2019 YTHDF1 promotes translation of CDK2, CDK4, and cyclin D1 mRNAs in an m6A-dependent manner in NSCLC cells, regulating cell cycle progression. YTHDF1 deficiency inhibited NSCLC cell proliferation and xenograft tumor formation. YTHDF1 depletion, translational efficiency measurements, xenograft models, mechanistic downstream target identification Nature communications Medium 31653849
2020 YTHDF1 binds m6A-modified EIF3C mRNA and augments EIF3C translation in an m6A-dependent manner in ovarian cancer, promoting overall translational output and tumorigenesis. EIF3C protein but not mRNA is increased in patient tumors and correlates with YTHDF1 protein levels. Multi-omics (m6A-seq, proteomics, RIP), YTHDF1 overexpression/KD, luciferase translation assays, patient tissue correlation Nucleic acids research High 31996915
2020 YTHDF1 facilitates translation of Wnt signaling effectors including TCF7L2/TCF4 in intestinal stem cells (ISCs), and this translation is enhanced during Wnt activation. Genetic ablation of Ythdf1 blocked Wnt-driven intestinal regeneration and tumorigenesis with reduced ISC stemness. Ythdf1 knockout mice, intestinal regeneration models, Wnt activation experiments, translational target identification EMBO reports High 32064749
2021 YTHDF1 directs translation of Traf6 mRNA via m6A modification near the stop codon in intestinal epithelial cells, regulating innate immune responses against bacterial pathogens. The P/Q/N-rich domain of YTHDF1 interacts with the DEAD domain of DDX60 to regulate this process. Ribo-seq, m6A-seq, RIP, domain interaction mapping (P/Q/N-rich domain vs. DEAD domain Co-IP), in vivo bacterial infection model Nucleic acids research High 33999206
2021 YTHDF1 promotes translation of ARHGEF2 mRNA by binding to its m6A sites in colorectal cancer, enhancing RhoA signaling and driving metastasis. Ectopic ARHGEF2 expression rescued impaired RhoA signaling and metastatic ability caused by YTHDF1 loss. Ythdf1 KO mouse, multiomics (RNA-seq, MeRIP-seq, RIP-seq, proteomics), in vitro/in vivo rescue experiments with ARHGEF2 Gastroenterology High 34968454
2021 YTHDF1 promotes translation of autophagy-related genes ATG2A and ATG14 by binding to m6A-modified ATG2A and ATG14 mRNAs in hepatocellular carcinoma. HIF-1α regulates YTHDF1 transcription by directly binding to its promoter under hypoxia, linking the hypoxia-YTHDF1-autophagy axis to HCC malignancy. MeRIP-seq, proteomics, polysome profiling, ChIP, luciferase reporter assays, YTHDF1 KO/OE HCC models, HCC organoids, PDX models Signal transduction and targeted therapy High 33619246
2021 ALKBH5-mediated m6A demethylation increases YTHDF1 mRNA stability, thereby upregulating YTHDF1 expression, which in turn promotes translation of YAP to facilitate cardiomyocyte proliferation and cardiac regeneration. ALKBH5 KO mice, AAV9 overexpression, human iPSC-derived cardiomyocytes, mechanistic epistasis (ALKBH5→m6A→YTHDF1→YAP) Theranostics Medium 33456585
2021 YTHDF1 promotes translation of ZNF839 (Zfp839) in bone marrow mesenchymal stem cells (BMSCs) in an m6A-dependent manner. Zfp839 interacts with and enhances the transcriptional activity of Runx2. Ythdf1 KO mice display decreased bone mass. Ythdf1 KO mice (bone mass phenotype), MeRIP-seq, RIP-seq, shRNA KD in human BMSCs, interaction studies (Zfp839-Runx2) Cell death & disease Medium 34772913
2021 YTHDF1 interacts with AGO2 through its YTH domain and promotes mRNA degradation via liquid-liquid phase separation (LLPS) and P-body formation. Deletion of YTHDF1 prolongs mRNA half-life, disrupts P-body liquid state (converting to gel/solid), and impairs miRNA-mediated mRNA degradation. CRISPR/Cas9 KO (HEK293, HeLa), 4SU-TT-seq for mRNA half-life, Co-IP (domain mapping), immunofluorescence co-localization, in vitro and in vivo phase separation assays, FRAP Cell proliferation High 34821414
2021 YTHDF1 promotes translation of cyclin E2 in an m6A-dependent manner in AML cells, driving leukemia stem cell self-renewal and AML progression. The FDA-approved drug tegaserod was identified as a YTHDF1 inhibitor that blocks YTHDF1-m6A-modified mRNA binding and inhibits cyclin E2 translation. Structure-based virtual screening, YTHDF1 depletion in primary human and mouse AML cells, translation assays, patient-derived xenograft models Cancer research Medium 36634204
2021 YTHDF1 promotes translation of Yes-associated protein (YAP) mRNA in renal fibrosis, and YTHDF1 knockdown reduces YAP expression and alleviates fibrosis. YTHDF1 binding to YAP mRNA was confirmed by RNA binding protein immunoprecipitation. RIP, YTHDF1 KD in fibrotic cell/mouse models (UUO), YAP rescue experiments FASEB journal Medium 34990050
2022 YTHDF1 promotes mRNA stability of E2F8 in a METTL14-dependent m6A manner, facilitating DNA damage repair and S-phase entry in breast cancer cells. YTHDF1 knockdown sensitizes cells to Adriamycin, Cisplatin, and Olaparib. Loss-of-function studies, in vitro/in vivo growth assays, DNA repair readouts, METTL14 dependency experiments Cell death & disease Medium 35279688
2022 YTHDF1 promotes NLRP3 translation in macrophages, enhancing IL-1β production during bacterial infection and inflammation. In vivo YTHDF1 knockdown improves survival in a mouse sepsis model. YTHDF1 OE/KD, NLRP3 translation assays, in vivo sepsis mouse model Biochemical and biophysical research communications Medium 35649302
2022 O-GlcNAcylation of YTHDF1 at Ser196/Ser197/Ser198 by OGT promotes cytosolic localization of YTHDF1 by enhancing its binding with the nuclear export protein Crm1, thereby increasing YTHDF1-driven translation of downstream targets (e.g., c-Myc) and colorectal cancer tumorigenesis. OGT Co-IP, site-directed mutagenesis (AFA mutant), Crm1 binding assays, molecular dynamics simulation, mouse xenograft The Journal of biological chemistry High 37086786
2022 YTHDF1 promotes translation of WWP1 mRNA in an m6A-dependent manner, leading to NLRP3 ubiquitination and inhibition of caspase-1-dependent pyroptosis in sepsis. RIP-RT-qPCR, dual luciferase reporter assay, meRIP, immunoprecipitation (NLRP3 ubiquitination), in vivo CLP model Cell death discovery Medium 35508474
2022 METTL3 induces m6A modification of CDC25B mRNA in the M phase of the cell cycle, which is recognized by YTHDF1 to accelerate CDC25B translation and promote cell cycle progression. METTL3 OE/KD, m6A modification assay (MeRIP), translation efficiency readout, YTHDF1 dependency experiments International journal of biological sciences Medium 35637959
2022 YTHDF1 and YTHDF2 synergistically control cerebellar granule cell (GC) axon growth by regulating local translation of Dvl1 (via YTHDF1) and Wnt5a (via YTHDF2) in axons. Specific ablation of Ythdf1 in GCs increases parallel fiber growth, promotes synapse formation, and improves motor coordination. RIP-Seq, quantitative proteomics, RNA-seq after KD, Ythdf1 conditional KO in GCs, in vivo cerebellum phenotype analysis Advanced science High 34643063
2023 YTHDF1 promotes translation of p65/RelA mRNA in an m6A-dependent manner in colorectal cancer cells, upregulating CXCL1 secretion, which recruits myeloid-derived suppressor cells (MDSCs) via CXCL1-CXCR2 axis to suppress CD8+ T cell antitumor activity. Ythdf1 KO (syngeneic tumors, Ythdf1 knockin mice), MeRIP-seq + RNA-seq + Ribo-seq integration, scRNA-seq immune profiling Gut High 36717220
2023 YTHDF1 binds to m6A-modified EZH2 mRNA and promotes EZH2 translation in NASH-HCC cells; EZH2 in turn increases IL-6 expression and secretion, which recruits and activates MDSCs to suppress CD8+ T cell function. RNA-seq, m6A-seq, RIP-seq, proteomics, ribosome profiling, scRNA-seq, flow cytometry, syngeneic allograft models Journal of hepatology High 37459919
2023 Tumor-intrinsic YTHDF1 drives immune evasion by increasing translation of lysosomal genes, promoting lysosomal proteolysis of MHC-I and antigens, thereby suppressing tumor immune surveillance. YTHDF1 deficiency restores MHC-I surface expression and antitumor immunity. YTHDF1 KD/KO, lysosomal gene translation assays, MHC-I surface expression measurement, exosome-mediated CRISPR/Cas9 delivery in vivo Nature communications Medium 36650153
2023 FMRP sequesters YTHDF1 away from ribosomes to suppress translation of YTHDF1 target mRNAs. Upon neuronal stimulation, FMRP becomes phosphorylated and releases YTHDF1, enabling YTHDF1 to condense with ribosomal proteins and promote translation of m6A-modified neuronal mRNAs. Co-IP (FMRP-YTHDF1), ribosome association assays, phosphorylation studies, neuronal stimulation experiments, FXS organoid model with small-molecule YTHDF1 inhibitor Molecular cell High 37949069
2023 m6A-modified circSAV1 forms an RNA-protein ternary complex with YTHDF1 and IREB2 mRNA, facilitating IREB2 translation. Elevated IREB2 disrupts iron homeostasis, causing labile iron pool accumulation and lipid peroxidation that triggers ferroptosis in lung epithelial cells in COPD. circRNA-seq, knockdown of circSAV1, RIP, ternary complex characterization, iron/ferroptosis assays, in vivo COPD model Cell death and differentiation Medium 36828914
2023 YTHDF1 binds m6A-modified NOTCH1 mRNA to enhance both its stability and translation in hepatocellular carcinoma stem cells, leading to increased NOTCH1 target gene expression and promoting HCC stemness and resistance to lenvatinib/sorafenib. Catalytically inactive YTHDF1 mutant abolishes this effect. RIP-seq, MeRIP-seq, ribosome profiling, RNA-seq, catalytically inactive mutant, patient-derived organoids, conditional Ythdf1 knockin mice Cancer research High 38241695
2023 RBMS1 interacts with YTHDF1 (via RBMS1 RRM2 motif and YTHDF1 YTH domain) to promote translation of S100P mRNA, accelerating NSCLC cell metastasis. Loss of RBMS1 inhibits S100P translation and suppresses metastasis in vivo. Co-IP (domain mapping), translation assays, in vivo metastasis models, domain mutagenesis Advanced science Medium 38342601
2023 YTHDF1 promotes translation of EZH2 mRNA in colorectal cancer (CRC) by binding to m6A-modified YTHDF1 mRNA in a feedforward circuit with RUVBL1/2. RUVBL1/2 interact with YTHDF1 at 40S translation initiation complexes, and RUVBL1/2 depletion stalls YTHDF1-driven oncogenic translation. CRISPR screening, Co-IP + mass spectrometry (YTHDF1-RUVBL1/2 interaction), Ribo-seq, MeRIP-seq, pharmacological inhibition (CB6644), in vivo xenografts Cancer research High 38900944
2024 YTHDF1 promotes translation of SLC7A11 mRNA in an m6A-dependent manner in nucleus pulposus cells, increasing GPX4 expression and suppressing ferroptosis. HIF-1α directly binds the YTHDF1 promoter to transcriptionally induce YTHDF1 under hypoxia. Luciferase reporter + ChIP (HIF-1α→YTHDF1 promoter), polysome profiling (SLC7A11 translation), RIP, in vitro/in vivo KO and OE models Aging cell Medium 38783692
2024 YTHDF1 recognizes m6A-modified PIEZO2 mRNA at a specific site (peak_26355) and promotes PIEZO2 translation in cardiac fibroblasts, driving fibroblast autophagy and cardiac fibrosis. Site-specific m6A modifications are required for YTHDF1-PIEZO2 mRNA binding. RNA-seq, single-cell sequencing, MeRIP-seq, site-specific m6A mutagenesis, AAV-delivered shYTHDF1, Piezo2 reconstitution in YTHDF1-deficient CFs and mice Cardiovascular research Medium 39498803
2024 SFTSV virulence factor NSs induces lactylation of YTHDF1, causing its degradation. This counters host YTHDF1-mediated destabilization and translational repression of m6A-modified SFTSV RNA, thereby facilitating viral replication. MeRIP-seq (SFTSV RNA m6A mapping), YTHDF1 binding assays, lactylation mass spectrometry, SFTSV infection models EMBO reports Medium 39496835
2024 DHX36 binding increases structural accessibility at 3'UTR m6A sites, facilitating YTHDF1 binding to these sites and leading to RNA degradation. DHX36-induced RNA structural remodeling thus regulates mRNA abundance through m6A-dependent YTHDF1 binding. RNA structurome profiling, m6A-seq, YTHDF1 RIP, DHX36 depletion experiments, transcriptome-wide correlation analyses Nature communications Medium 39543097
2024 Radiotherapy (RT) increases YTHDF1 expression in dendritic cells via STING/IFN-I signaling. YTHDF1 in turn promotes lysosomal cathepsin translation, triggering STING degradation and reducing IFN-I production in a negative feedback loop. Loss of YTHDF1 in DCs enhances cross-priming and antitumor effects of RT. Patient PBMC analysis, Ythdf1 DC-specific KO, multiple murine cancer models, STING/IFN-I pathway assays, DC vaccine prototype The Journal of clinical investigation High 39325547
2024 NAT10 phase separation promotes acetylation of splicing factor SRSF2, which directly binds YTHDF1 pre-mRNA and enhances YTHDF1 exon 4 skipping, generating a short YTHDF1 transcript that stimulates gastric cancer cell proliferation and migration. Phase separation assays, SRSF2 acetylation by NAT10 (in vitro), SRSF2-pre-mRNA binding (RIP), splicing analysis, functional rescue experiments Cancer research Medium 39024555
2024 YTHDF1 binds m6A-modified EZH2 and CDH11 mRNAs to promote their translation in breast cancer cells, driving osteolytic bone metastasis. shYTHDF1 delivered by AAV in intratibial injection models suppressed bone metastatic formation. RNA-seq + MeRIP-seq + RIP-seq + molecular biology, in vivo intratibial model with AAV-shYTHDF1 Cancer letters Medium 38871245
2024 H3K18 lactylation in arsenite-exposed alveolar epithelial cells promotes transcription of YTHDF1; elevated YTHDF1 then binds m6A-modified NREP mRNA to promote its translation, increasing TGF-β1 secretion and fibroblast-to-myofibroblast transition in pulmonary fibrosis. MeRIP-seq, RNA-seq, ChIP-seq, YTHDF1 KD/OE, ChIP-PCR validation, fibrosis readouts Journal of hazardous materials Medium 37742376
2024 YTHDF1 promotes translation of PLK1 mRNA by recognizing m6A modifications, activating the PI3K/AKT signaling pathway in prostate cancer. The transcription factor ELK1 directly binds the YTHDF1 promoter to drive its upregulation. Multi-omics for target identification, translation efficiency assays, ChIP (ELK1→YTHDF1 promoter), luciferase reporter, in vivo tumor and metastasis models International journal of biological sciences Medium 36439881
2023 m6A-modified lincRNA Dubr interacts with YTHDF1/3 complex through its m6A motifs to protect YTHDF1/3 from proteasomal degradation. This stabilization of YTHDF1/3 promotes translation of Tau and Calmodulin, facilitating neuronal axon elongation and cortical neuron migration. Dubr KD, m6A site mutagenesis of Dubr, YTHDF1/3 protein stability assays, YTHDF1/3 overexpression rescue, in vivo axon projection analysis Cell reports Medium 36417851
2024 YTHDF1 accumulates m6A-modified mRNAs in stress granules (SGs) in renal tubular cells under stress, safeguarding pro-survival mRNAs (e.g., SHPK1) from degradation. Renal tubular-specific YTHDF1 KO mice show heightened acute kidney injury severity. AKI patient samples, multiple mouse AKI models, tubular-specific YTHDF1 KO, m6A-modified mRNA SG co-localization assays, apoptosis readouts Redox biology Medium 37857002
2022 YTHDF1 binds to and increases the mRNA stability of PTEN in neurons, and YTHDF1 knockdown activates PI3K/AKT/mTOR pathway by promoting PTEN degradation, attenuating cerebral stroke injury. YTHDF1-PTEN mRNA binding was confirmed by luciferase assay and RIP. MCAO mouse model, YTHDF1 KD, luciferase assay, RIP, PTEN rescue experiments, western blot Molecular biotechnology Low 36261761
2024 YTHDF1 augments CLOCK translation in an m6A-dependent manner in airway epithelial cells. Allergens enhance YTHDF1 liquid-liquid phase separation and formation of a dimeric YTHDF1-CLOCK mRNA complex in stress granules, activating NLRP3 inflammasome and IL-1β secretion to drive allergic airway inflammation. YTHDF1 OE/KD, m6A-dependent translation assay, LLPS assays, CLOCK mRNA RIP, NLRP3/IL-1β readouts, CLOCK deletion rescue Cell reports Medium 38492220
2024 YTHDF1 binds m6A-modified FOXM1 mRNA and promotes FOXM1 mRNA stability (recognized by YTHDF1 downstream of KIAA1429-mediated methylation), increasing FOXM1 expression and aerobic glycolysis in multiple myeloma. RIP (YTHDF1-FOXM1 mRNA), m6A modification assay, YTHDF1 KD + FOXM1 OE rescue, glycolysis assays, in vivo xenograft Cell biology and toxicology Medium 39060874
2024 Methionine-elevated YTHDF1 promotes degradation of RIG-I mRNA, suppressing RIG-I/MAVS-mediated IFN-I pathway. Additionally, YTHDF1 binds eIF5B to enhance PD-L1 mRNA translation, promoting immune evasion in bladder cancer. RNA-seq, point mutations, MB49 mouse tumor models, scRNA-seq, immunoprecipitation + mass spectrometry (YTHDF1-eIF5B interaction), PD-L1 translation assays Cell death and differentiation Medium 39672819

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2019 Anti-tumour immunity controlled through mRNA m6A methylation and YTHDF1 in dendritic cells. Nature 787 30728504
2020 The m6A reader YTHDF1 promotes ovarian cancer progression via augmenting EIF3C translation. Nucleic acids research 587 31996915
2018 m6A facilitates hippocampus-dependent learning and memory through YTHDF1. Nature 430 30401835
2021 HIF-1α-induced expression of m6A reader YTHDF1 drives hypoxia-induced autophagy and malignancy of hepatocellular carcinoma by promoting ATG2A and ATG14 translation. Signal transduction and targeted therapy 325 33619246
2019 YTHDF1 links hypoxia adaptation and non-small cell lung cancer progression. Nature communications 305 31653849
2019 YTHDF1 Regulates Tumorigenicity and Cancer Stem Cell-Like Activity in Human Colorectal Carcinoma. Frontiers in oncology 210 31131257
2023 Targeting m6A reader YTHDF1 augments antitumour immunity and boosts anti-PD-1 efficacy in colorectal cancer. Gut 196 36717220
2017 Oncogene c-Myc promotes epitranscriptome m6A reader YTHDF1 expression in colorectal cancer. Oncotarget 190 29484125
2019 The m6A reader YTHDF1 regulates axon guidance through translational control of Robo3.1 expression. Nucleic acids research 161 30843071
2021 N6-Methyladenosine Reader YTHDF1 Promotes ARHGEF2 Translation and RhoA Signaling in Colorectal Cancer. Gastroenterology 158 34968454
2021 ALKBH5 regulates cardiomyocyte proliferation and heart regeneration by demethylating the mRNA of YTHDF1. Theranostics 142 33456585
2022 YTHDF1 promotes breast cancer cell growth, DNA damage repair and chemoresistance. Cell death & disease 131 35279688
2023 N6-Methyladenosine-modified circSAV1 triggers ferroptosis in COPD through recruiting YTHDF1 to facilitate the translation of IREB2. Cell death and differentiation 126 36828914
2023 H3K18 lactylation promotes the progression of arsenite-related idiopathic pulmonary fibrosis via YTHDF1/m6A/NREP. Journal of hazardous materials 120 37742376
2020 m6A-YTHDF1-mediated TRIM29 upregulation facilitates the stem cell-like phenotype of cisplatin-resistant ovarian cancer cells. Biochimica et biophysica acta. Molecular cell research 116 33011193
2023 Targeting N6-methyladenosine reader YTHDF1 with siRNA boosts antitumor immunity in NASH-HCC by inhibiting EZH2-IL-6 axis. Journal of hepatology 111 37459919
2020 YTHDF1-mediated translation amplifies Wnt-driven intestinal stemness. EMBO reports 102 32064749
2021 Mettl3 inhibits the apoptosis and autophagy of chondrocytes in inflammation through mediating Bcl2 stability via Ythdf1-mediated m6A modification. Bone 91 34530171
2019 m6A methylation controls pluripotency of porcine induced pluripotent stem cells by targeting SOCS3/JAK2/STAT3 pathway in a YTHDF1/YTHDF2-orchestrated manner. Cell death & disease 91 30787270
2023 Tumor-intrinsic YTHDF1 drives immune evasion and resistance to immune checkpoint inhibitors via promoting MHC-I degradation. Nature communications 89 36650153
2021 The N6-methyladenosine RNA-binding protein YTHDF1 modulates the translation of TRAF6 to mediate the intestinal immune response. Nucleic acids research 88 33999206
2022 Loss of YTHDF1 in gastric tumors restores sensitivity to antitumor immunity by recruiting mature dendritic cells. Journal for immunotherapy of cancer 83 35193930
2021 YTHDF1 promotes mRNA degradation via YTHDF1-AGO2 interaction and phase separation. Cell proliferation 81 34821414
2021 YTHDF1 promotes hepatocellular carcinoma progression via activating PI3K/AKT/mTOR signaling pathway and inducing epithelial-mesenchymal transition. Experimental hematology & oncology 77 34088349
2023 The RNA m6A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression. Cancer research 76 36634204
2022 m6 A Reader YTHDF1-Targeting Engineered Small Extracellular Vesicles for Gastric Cancer Therapy via Epigenetic and Immune Regulation. Advanced materials (Deerfield Beach, Fla.) 75 36484103
2024 N6-Methyladenosine Reader YTHDF1 Promotes Stemness and Therapeutic Resistance in Hepatocellular Carcinoma by Enhancing NOTCH1 Expression. Cancer research 74 38241695
2018 MTCH2 promotes adipogenesis in intramuscular preadipocytes via an m6A-YTHDF1-dependent mechanism. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 74 30339471
2022 YTHDF1 upregulation mediates hypoxia-dependent breast cancer growth and metastasis through regulating PKM2 to affect glycolysis. Cell death & disease 71 35319018
2022 YTHDF1 alleviates sepsis by upregulating WWP1 to induce NLRP3 ubiquitination and inhibit caspase-1-dependent pyroptosis. Cell death discovery 69 35508474
2023 FMRP phosphorylation modulates neuronal translation through YTHDF1. Molecular cell 64 37949069
2020 Musashi-1 promotes cancer stem cell properties of glioblastoma cells via upregulation of YTHDF1. Cancer cell international 56 33317545
2020 Oncogenic Role of an Epigenetic Reader of m6A RNA Modification: YTHDF1 in Merkel Cell Carcinoma. Cancers 50 31947544
2021 Analysis and Validation of circRNA-miRNA Network in Regulating m6A RNA Methylation Modulators Reveals CircMAP2K4/miR-139-5p/YTHDF1 Axis Involving the Proliferation of Hepatocellular Carcinoma. Frontiers in oncology 48 33708621
2024 WTAP participates in neuronal damage by protein translation of NLRP3 in an m6A-YTHDF1-dependent manner after traumatic brain injury. International journal of surgery (London, England) 47 38874470
2023 N6-methyladenosine regulator YTHDF1 represses the CD8 + T cell-mediated antitumor immunity and ferroptosis in prostate cancer via m6A/PD-L1 manner. Apoptosis : an international journal on programmed cell death 47 37698736
2023 The function and clinical implication of YTHDF1 in the human system development and cancer. Biomarker research 46 36650570
2021 The m6A "reader" YTHDF1 promotes osteogenesis of bone marrow mesenchymal stem cells through translational control of ZNF839. Cell death & disease 46 34772913
2020 Differential roles of YTHDF1 and YTHDF3 in embryonic stem cell-derived cardiomyocyte differentiation. RNA biology 43 33295243
2022 ELK1-mediated YTHDF1 drives prostate cancer progression by facilitating the translation of Polo-like kinase 1 in an m6A dependent manner. International journal of biological sciences 42 36439881
2021 The m6 A Readers YTHDF1 and YTHDF2 Synergistically Control Cerebellar Parallel Fiber Growth by Regulating Local Translation of the Key Wnt5a Signaling Components in Axons. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 41 34643063
2024 HIF-1α-induced expression of the m6A reader YTHDF1 inhibits the ferroptosis of nucleus pulposus cells by promoting SLC7A11 translation. Aging cell 40 38783692
2022 METTL3 promotes cell cycle progression via m6A/YTHDF1-dependent regulation of CDC25B translation. International journal of biological sciences 40 35637959
2020 Increased expression of YTHDF1 and HNRNPA2B1 as potent biomarkers for melanoma: a systematic analysis. Cancer cell international 37 32549786
2021 Potential Impact of ALKBH5 and YTHDF1 on Tumor Immunity in Colon Adenocarcinoma. Frontiers in oncology 36 34079761
2022 RNA Editing Enzyme ADAR1 Regulates METTL3 in an Editing Dependent Manner to Promote Breast Cancer Progression via METTL3/ARHGAP5/YTHDF1 Axis. International journal of molecular sciences 35 36077054
2023 O-GlcNAcylation promotes the cytosolic localization of the m6A reader YTHDF1 and colorectal cancer tumorigenesis. The Journal of biological chemistry 34 37086786
2023 The potential role of m6A reader YTHDF1 as diagnostic biomarker and the signaling pathways in tumorigenesis and metastasis in pan-cancer. Cell death discovery 32 36707507
2021 The protective role of YTHDF1-knock down macrophages on the immune paralysis of severe sepsis rats with ECMO. Microvascular research 31 34015275
2022 Involvement of YTHDF1 in renal fibrosis progression via up-regulating YAP. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 30 34990050
2022 m6A-modified lincRNA Dubr is required for neuronal development by stabilizing YTHDF1/3 and facilitating mRNA translation. Cell reports 29 36417851
2023 m6A methyltransferase WTAP regulates myocardial ischemia reperfusion injury through YTHDF1/FOXO3a signaling. Apoptosis : an international journal on programmed cell death 27 36894806
2023 A novel MYCN-YTHDF1 cascade contributes to retinoblastoma tumor growth by eliciting m6A -dependent activation of multiple oncogenes. Science China. Life sciences 27 36949231
2022 METTL3 promotes proliferation and myogenic differentiation through m6A RNA methylation/YTHDF1/2 signaling axis in myoblasts. Life sciences 27 35351467
2021 YTHDF1 promotes the proliferation, migration, and invasion of prostate cancer cells by regulating TRIM44. Genes & genomics 26 34677810
2024 NAT10 Phase Separation Regulates YTHDF1 Splicing to Promote Gastric Cancer Progression. Cancer research 25 39024555
2022 Mesenchymal stem cells-derived HIF-1α-overexpressed extracellular vesicles ameliorate hypoxia-induced pancreatic β cell apoptosis and senescence through activating YTHDF1-mediated protective autophagy. Bioorganic chemistry 24 36244321
2020 The N6-Methyladenosine (m6A) Methylation Gene YTHDF1 Reveals a Potential Diagnostic Role for Gastric Cancer. Cancer management and research 24 33244271
2024 RBMS1 Coordinates with the m6A Reader YTHDF1 to Promote NSCLC Metastasis through Stimulating S100P Translation. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 23 38342601
2022 Comprehensive Analysis of YTHDF1 Immune Infiltrates and ceRNA in Human Esophageal Carcinoma. Frontiers in genetics 23 35401696
2022 YTHDF1 regulates endoplasmic reticulum stress, NF-κB, MAPK and PI3K-AKT signaling pathways in inflammatory osteoclastogenesis. Archives of biochemistry and biophysics 23 36368367
2023 YTHDF1 Promotes Bladder Cancer Cell Proliferation via the METTL3/YTHDF1-RPN2-PI3K/AKT/mTOR Axis. International journal of molecular sciences 22 37108067
2022 METTL3 promotes m6A hypermethylation of RBM14 via YTHDF1 leading to the progression of hepatocellular carcinoma. Human cell 22 36087219
2024 Photosensitive and dual-targeted chromium nanoparticle delivering small interfering RNA YTHDF1 for molecular-targeted immunotherapy in liver cancer. Journal of nanobiotechnology 20 38898486
2022 RNA m6A reader YTHDF1 facilitates inflammation via enhancing NLRP3 translation. Biochemical and biophysical research communications 20 35649302
2024 YTHDF1 regulates GID8-mediated glutamine metabolism to promote colorectal cancer progression in m6A-dependent manner. Cancer letters 19 39151722
2024 hucMSC-Ex alleviates inflammatory bowel disease in mice by enhancing M2-type macrophage polarization via the METTL3-Slc37a2-YTHDF1 axis. Cell biology and toxicology 19 39259386
2024 YTHDF1 loss in dendritic cells potentiates radiation-induced antitumor immunity via STING-dependent type I IFN production. The Journal of clinical investigation 19 39325547
2024 Severe fever with thrombocytopenia syndrome virus induces lactylation of m6A reader protein YTHDF1 to facilitate viral replication. EMBO reports 19 39496835
2023 H19 recruited N 6 -methyladenosine (m 6 A) reader YTHDF1 to promote SCARB1 translation and facilitate angiogenesis in gastric cancer. Chinese medical journal 19 37279381
2023 ALKBH5 promotes hypopharyngeal squamous cell carcinoma apoptosis by targeting TLR2 in a YTHDF1/IGF2BP2-mediated manner. Cell death discovery 17 37612282
2021 The expression of m6A enzymes in the hippocampus of diabetic cognitive impairment mice and the possible improvement of YTHDF1. Brain research 17 34953798
2023 Inhibition of YTHDF1 prevents hypoxia-induced pulmonary artery smooth muscle cell proliferation by regulating Foxm1 translation in an m6A-dependent manner. Experimental cell research 16 36736607
2022 Silencing of YTHDF1 Attenuates Cerebral Stroke by Inducing PTEN Degradation and Activating the PTEN/AKT/mTOR Pathway. Molecular biotechnology 16 36261761
2024 YTHDF1-CLOCK axis contributes to pathogenesis of allergic airway inflammation through LLPS. Cell reports 15 38492220
2024 METTL3 promotes the osteogenic differentiation of human periodontal ligament cells by increasing YAP activity via IGF2BP1 and YTHDF1-mediated m6A modification. Journal of periodontal research 15 38838034
2024 YTHDF1 promotes the osteolytic bone metastasis of breast cancer via inducing EZH2 and CDH11 translation. Cancer letters 15 38871245
2024 DUSP5 regulated by YTHDF1-mediated m6A modification promotes epithelial-mesenchymal transition and EGFR-TKI resistance via the TGF-β/Smad signaling pathway in lung adenocarcinoma. Cancer cell international 15 38872157
2024 KIAA1429 increases FOXM1 expression through YTHDF1-mediated m6A modification to promote aerobic glycolysis and tumorigenesis in multiple myeloma. Cell biology and toxicology 15 39060874
2023 PLAGL2 promotes Snail expression and gastric cancer progression via UCA1/miR-145-5p/YTHDF1 axis. Carcinogenesis 15 36999803
2023 Propofol suppresses OGD/R-induced ferroptosis in neurons by inhibiting the HIF-1α/YTHDF1/BECN1 axis. Brain injury 15 37614036
2021 YTHDF1 gene polymorphisms and neuroblastoma susceptibility in Chinese children: an eight-center case-control study. Journal of Cancer 15 33758623
2024 FTO mediates bisphenol F-induced blood-testis barrier impairment through regulating ferroptosis via YTHDF1/TfRc and YTHDF2/SLC7A11 signal axis. Environmental pollution (Barking, Essex : 1987) 14 38996995
2024 Epitranscriptomic regulation of cardiac fibrosis via YTHDF1-dependent PIEZO2 mRNA m6A modification. Cardiovascular research 14 39498803
2024 YTHDF1 boosts the lactate accumulation to potentiate cervical cancer cells immune escape. Cell death & disease 14 39557826
2023 The m6A Reader YTHDF1 Promotes Lung Carcinoma Progression via Regulating Ferritin Mediate Ferroptosis in an m6A-Dependent Manner. Pharmaceuticals (Basel, Switzerland) 14 37259333
2023 The m6A Reader YTHDF1 Improves Sevoflurane-Induced Neuronal Pyroptosis and Cognitive Dysfunction Through Augmenting CREB-BDNF Signaling. Neurochemical research 14 37572160
2021 m6A RNA Methylation Regulator YTHDF1 Correlated With Immune Microenvironment Predicts Clinical Outcomes and Therapeutic Efficacy in Breast Cancer. Frontiers in medicine 14 34434939
2021 LncRNA LINC00337 sponges mir-1285-3p to promote proliferation and metastasis of lung adenocarcinoma cells by upregulating YTHDF1. Cancer cell international 14 34663343
2024 Targeting METTL3 enhances the chemosensitivity of non-small cell lung cancer cells by decreasing ABCC2 expression in an m6A-YTHDF1-dependent manner. International journal of biological sciences 13 39309428
2024 RUVBL1/2 Blockade Targets YTHDF1 Activity to Suppress m6A-Dependent Oncogenic Translation and Colorectal Tumorigenesis. Cancer research 12 38900944
2024 Gegen Qinlian Decoction reverses oxaliplatin resistance in colorectal cancer by inhibiting YTHDF1-regulated m6A modification of GLS1. Phytomedicine : international journal of phytotherapy and phytopharmacology 12 39089089
2023 YTHDF1 mitigates acute kidney injury via safeguarding m6A-methylated mRNAs in stress granules of renal tubules. Redox biology 12 37857002
2023 Usf2 Deficiency Promotes Autophagy to Alleviate Cerebral Ischemia-Reperfusion Injury Through Suppressing YTHDF1-m6A-Mediated Cdc25A Translation. Molecular neurobiology 12 37914905
2022 MEF2C Expression Is Regulated by the Post-transcriptional Activation of the METTL3-m6A-YTHDF1 Axis in Myoblast Differentiation. Frontiers in veterinary science 12 35573410
2022 Wnt3a/YTHDF1 Regulated Oxaliplatin-Induced Neuropathic Pain Via TNF-α/IL-18 Expression in the Spinal Cord. Cellular and molecular neurobiology 12 35939138
2022 Mettl3 regulates hypertrophic differentiation of chondrocytes through modulating Dmp1 mRNA via Ythdf1-mediated m6A modification. Bone 12 35981698
2024 Mettl3-m6A-YTHDF1 axis promotion of mitochondrial dysfunction in metabolic dysfunction-associated steatotic liver disease. Cellular signalling 11 39019337
2024 DHX36 binding induces RNA structurome remodeling and regulates RNA abundance via m6A reader YTHDF1. Nature communications 11 39543097
2024 Methionine-driven YTHDF1 expression facilitates bladder cancer progression by attenuating RIG-I-modulated immune responses and enhancing the eIF5B-PD-L1 axis. Cell death and differentiation 11 39672819